维普期刊资源整合服务平台（V6.5）

38篇 您的检索式：作者名="TUXEN MK"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Serum tumor marker CA125 for monitoring ovarian cancer dur- ing follow-up显示文摘	Tuxen MK Soletormos G Dombernowsky P	2002	Scand J Clin Lab Invest2002，62，24：	1
2	Defining progression of ovarian carcinoma during follow-up according to CA 125:a North Thames Ovary Group Study显示文摘	Rustin GJ Nelstrop AE Tuxen MK	1996	Ann Oncol1996，7，4：	1
3	Defining progression of ovarian carcinoma during follow-up according to CA125:a North Thames Ovary Group Study显示文摘	Rustin GJ Nelstrop AE Tuxen MK	1996	Ann Oncol1996，7，：	1
4	Treatmerit of elderly patients with breast cancer显示文摘	Paaschburg B Pedersen A Tuxen MK	2008	Ugeskr Laeger2008，170，：	1
5	ExploratoryphaseⅢstudy of paclitaxel and cisplatin versus paclitaxeland carboplatin in advanced ovarian cancer显示文摘	Neijt JP Engelholm SA Tuxen MK	2000	J Clin On-col2000，18，17：	1
6	Exploratory phase I]I study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer 显示文摘	Neijt JP Engelholm SA Tuxen MK	2000	J Clin Oncol2000，18，30：	1
7	Serum marker CA125 in monitoring of ovarian cancer during first-line chemotherapy显示文摘	Tuxen MK Soletomos G Dombemowsky P		0，，10：	1
8	Defining progression of ovari- an carcinoma during follow-up according to CA 125 :a north thames o- vary group study 显示文摘	Rustin GJ Nelstrop AE Tuxen MK	1996	Ann Oncol1996，7，2：	1
9	Exploratory phase Ⅲ study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer显示文摘	Neijt JP Engelholm SA Tuxen MK	2000	J Clin Oncol2000，18，17：	1
10	Biological variationand analytical imprecision of CA 125 in patients with ovariancancer显示文摘	Tuxen MK Soletormos G Rustin GJ	2000	Scand J Clin Lab Invest2000，60，：	1
11	Serum tumormarker CA 125 for monitoring ovarian cancer during follow-up显示文摘	Tuxen MK Soletormos G Dombernowsky P	2002	Scand J Clin Lab Invest2002，62，：	1
12	Defining progression of ovarian carcinoma during follow-up according to CA125 :a North Thames Ovary Group Study显示文摘	Rustin GJ Nelstrop AE Tuxen MK	1996	Ann Oncol1996，7，：	1
13	Serum marker CA125 in monitoring of ovarian cancer during first-line chemotherapy显示文摘	Tuxen MK Soletormos G Dombemowsky P	2001	Br J Cancer2001，84，10：	1
14	Exploratory phase Ⅲ study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer显示文摘	Neijt JP Engelholm SA Tuxen MK	2000	J Clin Oncol2000，18，17：	1
15	Defining progression of ovarian carcinoma during follow-up according to CA 125:a North Thames Ovary Group Study显示文摘	Rustin GJ Nelstrop AE Tuxen MK		0，，：	1
16	Exploratory phase Ⅲ study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer 显示文摘	Neijt JP Engelhom SA Tuxen MK	2008	J Clin Oncol2008，18，17：	1
17	Tumor markers in the management of patients with ovarian cancer显示文摘	TUXEN MK SOLITORMOS G DOMBERNOWSKY P	1995	Cancer Treat Rev1995，21，3：	1
18	Assessment of biological vari-ation and analytical imprecision of CA125,CEA,and TPA in relation to mo-nitoring of ovarian cancer显示文摘	Tuxen MK Soletormos G Petersen PH	1999	Gynecol Oncol1999，74，：	1
19	Serum tumour marker CA125 in monitoring of ovarian cancer during first-line chemotherapy显示文摘	Tuxen MK Soletormos G Dombernowsky P	2001	Br J Canc-er2001，84，：	1
20	Exploratory phase II study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer显示文摘	Neijt JP Engelholm SA Tuxen MK	2000	J Clin Oncol2000，18，17：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示